|
1
|
Andersen N, Froman R, Kitchell B and
Duesbery N: Angiosarcoma, clinical and molecular aspects. Soft
Tissue Sarcoma. Derbel F: I-Tech Education and Publishing; Rijeka,
Croatia: pp. 149–174. 2011
|
|
2
|
Young RJ, Brown NJ, Reed MW, Hughes D and
Woll PJ: Angiosarcoma. Lancet Oncol. 11:983–991. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Behjati S, Tarpey PS, Sheldon H,
Martincorena I, Van Loo P, Gundem G, Wedge DC, Ramakrishna M, Cooke
SL, Pillay N, et al: Recurrent PTPRB and PLCG1 mutations in
angiosarcoma. Nat Genet. 46:376–379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marion MJ, Froment O and Trépo C:
Activation of Ki-ras gene by point mutation in human liver
angiosarcoma associated with vinyl-chloride exposure. Mol Carcinog.
4:450–454. 1991. View Article : Google Scholar
|
|
5
|
Przygodzki RM, Finkelstein SD, Keohavong
P, Zhu D, Bakker A, Swalsky PA, Soini Y, Ishak KG and Bennett WP:
Sporadic and Thorotrast-induced angiosarcomas of the liver manifest
frequent and multiple point mutations in K-ras-2. Lab Invest.
76:153–159. 1997.PubMed/NCBI
|
|
6
|
Weihrauch M, Bader M, Lehnert G, Koch B,
Wittekind C, Wrbitzky R and Tannapfel A: Mutation analysis of
K-ras-2 in liver angiosarcoma and adjacent nonneoplastic liver
tissue from patients occupationally exposed to vinyl chloride.
Environ Mol Mutagen. 40:36–40. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Antonescu CR, Yoshida A, Guo T, Chang NE,
Zhang L, Agaram NP, Qin LX, Brennan MF, Singer S and Maki RG: KDR
activating mutations in human angiosarcomas are sensitive to
specific kinase inhibitors. Cancer Res. 69:7175–7179. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Andersen NJ, Nickoloff BJ, Dykema KJ,
Boguslawski EA, Krivochenitser RI, Froman RE, Dawes MJ, Baker LH,
Thomas DG, Kamstock DA, et al: Pharmacologic inhibition of MEK
signaling prevents growth of canine hemangiosarcoma. Mol Cancer
Ther. 12:1701–1714. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bromberg-White JL, Andersen NJ and
Duesbery NS: MEK genomics in development and disease. Brief Funct
Genomics. 11:300–310. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hoshino R, Chatani Y, Yamori T, Tsuruo T,
Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, et al:
Constitutive activation of the 41-/43-kDa mitogen-activated protein
kinase signaling pathway in human tumors. Oncogene. 18:813–822.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Platz A, Egyhazi S, Ringborg U and Hansson
J: Human cutaneous melanoma; a review of NRAS and BRAF mutation
frequencies in relation to histogenetic subclass and body site. Mol
Oncol. 1:395–405. 2008. View Article : Google Scholar
|
|
12
|
Shimo T, Matsumura S, Ibaragi S, Isowa S,
Kishimoto K, Mese H, Nishiyama A and Sasaki A: Specific inhibitor
of MEK-mediated cross-talk between ERK and p38 MAPK during
differentiation of human osteosarcoma cells. J Cell Commun Signal.
1:103–111. 2007. View Article : Google Scholar
|
|
13
|
Benini S, Manara MC, Cerisano V,
Perdichizzi S, Strammiello R, Serra M, Picci P and Scotlandi K:
Contribution of MEK/MAPK and PI3-K signaling pathway to the
malignant behavior of Ewing’s sarcoma cells: Therapeutic prospects.
Int J Cancer. 108:358–366. 2004. View Article : Google Scholar
|
|
14
|
Ding Y, Boguslawski EA, Berghuis BD, Young
JJ, Zhang Z, Hardy K, Furge K, Kort E, Frankel AE, Hay RV, et al:
Mitogen-activated protein kinase kinase signaling promotes growth
and vascularization of fibrosarcoma. Mol Cancer Ther. 7:648–658.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sodhi A, Montaner S, Patel V, Zohar M,
Bais C, Mesri EA and Gutkind JS: The Kaposi’s sarcoma-associated
herpes virus G protein-coupled receptor up-regulates vascular
endothelial growth factor expression and secretion through
mitogen-activated protein kinase and p38 pathways acting on
hypoxia-inducible factor 1alpha. Cancer Res. 60:4873–4880.
2000.PubMed/NCBI
|
|
16
|
Rinehart J, Adjei AA, Lorusso PM,
Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury
P, Kaldjian EP, et al: Multicenter phase II study of the oral MEK
inhibitor, CI-1040, in patients with advanced non-small-cell lung,
breast, colon, and pancreatic cancer. J Clin Oncol. 22:4456–4462.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Haura EB, Ricart AD, Larson TG, Stella PJ,
Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner
KD, et al: A phase II study of PD-0325901, an oral MEK inhibitor,
in previously treated patients with advanced non-small cell lung
cancer. Clin Cancer Res. 16:2450–2457. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
LoRusso PM, Krishnamurthi SS, Rinehart JJ,
Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner
KD, Tan W, et al: Phase I pharmacokinetic and pharmacodynamic study
of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with
advanced cancers. Clin Cancer Res. 16:1924–1937. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim KB, Kefford R, Pavlick AC, Infante JR,
Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, et
al: Phase II study of the MEK1/MEK2 inhibitor Trametinib in
patients with metastatic BRAF-mutant cutaneous melanoma previously
treated with or without a BRAF inhibitor. J Clin Oncol. 31:482–489.
2013. View Article : Google Scholar
|
|
20
|
Moore RD and Chaisson RE: Natural history
of HIV infection in the era of combination antiretroviral therapy.
AIDS. 13:1933–1942. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Al-Lazikani B, Banerji U and Workman P:
Combinatorial drug therapy for cancer in the post-genomic era. Nat
Biotechnol. 30:679–692. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zumla A, Nahid P and Cole ST: Advances in
the development of new tuberculosis drugs and treatment regimens.
Nat Rev Drug Discov. 12:388–404. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gerstung M, Eriksson N, Lin J, Vogelstein
B and Beerenwinkel N: The temporal order of genetic and pathway
alterations in tumorigenesis. PLoS One. 6:e271362011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee CS, Dykema KJ, Hawkins DM, Cherba DM,
Webb CP, Furge KA and Duesbery NS: MEK2 is sufficient but not
necessary for proliferation and anchorage-independent growth of
SK-MEL-28 melanoma cells. PLoS One. 6:e171652011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Woodman SE, Trent JC, Stemke-Hale K, Lazar
AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA,
et al: Activity of dasatinib against L576P KIT mutant melanoma:
Molecular, cellular, and clinical correlates. Mol Cancer Ther.
8:2079–2085. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Solit DB, Garraway LA, Pratilas CA, Sawai
A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, et al: BRAF
mutation predicts sensitivity to MEK inhibition. Nature.
439:358–362. 2006. View Article : Google Scholar
|
|
28
|
Frost P, Moatamed F, Hoang B, Shi Y, Gera
J, Yan H, Frost P, Gibbons J and Lichtenstein A: In vivo antitumor
effects of the mTOR inhibitor CCI-779 against human multiple
myeloma cells in a xenograft model. Blood. 104:4181–4187. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hidalgo M, Buckner JC, Erlichman C,
Pollack MS, Boni JP, Dukart G, Marshall B, Speicher L, Moore L and
Rowinsky EK: A phase I and pharmacokinetic study of temsirolimus
(CCI-779) administered intravenously daily for 5 days every 2 weeks
to patients with advanced cancer. Clin Cancer Res. 12:5755–5763.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yuan R, Kay A, Berg WJ and Lebwohl D:
Targeting tumorigenesis: Development and use of mTOR inhibitors in
cancer therapy. J Hematol Oncol. 2:452009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guenther MK, Graab U and Fulda S:
Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK
pathway inhibition in rhabdomyosarcoma. Cancer Lett. 337:200–209.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Renshaw J, Taylor KR, Bishop R, Valenti M,
De Haven Brandon A, Gowan S, Eccles SA, Ruddle RR, Johnson LD,
Raynaud FI, et al: Dual blockade of the PI3K/AKT/mTOR (AZD8055) and
RAS/MEK/ERK (AZD6244) pathways synergistically inhibits
rhabdomyosarcoma cell growth in vitro and in vivo. Clin Cancer Res.
19:5940–5951. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ho AL, Musi E, Ambrosini G, Nair JS,
Deraje Vasudeva S, de Stanchina E and Schwartz GK: Impact of
combined mTOR and MEK inhibition in uveal melanoma is driven by
tumor genotype. PLoS One. 7:e404392012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
She QB, Halilovic E, Ye Q, Zhen W,
Shirasawa S, Sasazuki T, Solit DB and Rosen N: 4E-BP1 is a key
effector of the oncogenic activation of the AKT and ERK signaling
pathways that integrates their function in tumors. Cancer Cell.
18:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gingras AC, Kennedy SG, O’Leary MA,
Sonenberg N and Hay N: 4E-BP1, a repressor of mRNA translation, is
phosphorylated and inactivated by the Akt(PKB) signaling pathway.
Genes Dev. 12:502–513. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ruggero D and Sonenberg N: The Akt of
translational control. Oncogene. 24:7426–7434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mills JR, Hippo Y, Robert F, Chen SM,
Malina A, Lin CJ, Trojahn U, Wendel HG, Charest A, Bronson RT, et
al: mTORC1 promotes survival through translational control of
Mcl-1. Proc Natl Acad Sci USA. 105:10853–10858. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Leevers SJ and Marshall CJ: Activation of
extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein.
EMBO J. 11:569–574. 1992.PubMed/NCBI
|
|
39
|
Graells J, Vinyals A, Figueras A, Llorens
A, Moreno A, Marcoval J, Gonzalez FJ and Fabra A: Overproduction of
VEGF concomitantly expressed with its receptors promotes growth and
survival of melanoma cells through MAPK and PI3K signaling. J
Invest Dermatol. 123:1151–1161. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu S, Huo J, Lee KG, Kurosaki T and Lam
KP: Phospholipase Cgamma2 is critical for Dectin-1-mediated
Ca2+ flux and cytokine production in dendritic cells. J
Biol Chem. 284:7038–7046. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang Q, Yu C, Peng S, Xu H, Wright E,
Zhang X, Huo X, Cheng E, Pham TH, Asanuma K, et al: Autocrine VEGF
signaling promotes proliferation of neoplastic Barrett’s epithelial
cells through a PLC-dependent pathway. Gastroenterology.
146:461–472 e6. 2014. View Article : Google Scholar
|
|
42
|
Renovanz M and Kim EL: Intratumoral
heterogeneity, its contribution to therapy resistance and
methodological caveats to assessment. Front Oncol. 4:1422014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ocana A, Amir E, Yeung C, Seruga B and
Tannock IF: How valid are claims for synergy in published clinical
studies? Ann Oncol. 23:2161–2166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Greco WR, Faessel H and Levasseur L: The
search for cytotoxic synergy between anticancer agents: A case of
Dorothy and the ruby slippers? J Natl Cancer Inst. 88:699–700.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhao L, Au JL and Wientjes MG: Comparison
of methods for evaluating drug-drug interaction. Front Biosci
(Elite Ed). 2:241–249. 2010. View
Article : Google Scholar
|
|
46
|
Engelman JA, Chen L, Tan X, Crosby K,
Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y,
et al: Effective use of PI3K and MEK inhibitors to treat mutant
Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med.
14:1351–1356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Faber AC, Li D, Song Y, Liang MC, Yeap BY,
Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, et
al: Differential induction of apoptosis in HER2 and EGFR addicted
cancers following PI3K inhibition. Proc Natl Acad Sci USA.
106:19503–19508. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jokinen E, Laurila N and Koivunen JP:
Alternative dosing of dual PI3K and MEK inhibition in cancer
therapy. BMC Cancer. 12:6122012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Posch C, Moslehi H, Feeney L, Green GA,
Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T,
et al: Combined targeting of MEK and PI3K/mTOR effector pathways is
necessary to effectively inhibit NRAS mutant melanoma in vitro and
in vivo. Proc Natl Acad Sci USA. 110:4015–4020. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang YJ, Tian XQ, Sun DF, Zhao SL, Xiong
H and Fang JY: Combined inhibition of MEK and mTOR signaling
inhibits initiation and progression of colorectal cancer. Cancer
Invest. 27:273–285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chang Q, Chen E and Hedley DW: Effects of
combined inhibition of MEK and mTOR on downstream signaling and
tumor growth in pancreatic cancer xenograft models. Cancer Biol
Ther. 8:1893–1901. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Depeille PE, Ding Y, Bromberg-White JL and
Duesbery NS: MKK signaling and vascularization. Oncogene.
26:1290–1296. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mansfield PJ, Shayman JA and Boxer LA:
Regulation of polymorphonuclear leukocyte phagocytosis by myosin
light chain kinase after activation of mitogen-activated protein
kinase. Blood. 95:2407–2412. 2000.PubMed/NCBI
|
|
54
|
Yuan TL and Cantley LC: PI3K pathway
alterations in cancer: Variations on a theme. Oncogene.
27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jia J, Zhu F, Ma X, Cao Z, Li Y and Chen
YZ: Mechanisms of drug combinations: Interaction and network
perspectives. Nat Rev Drug Discov. 8:111–128. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah
G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I,
Nagy JA, et al: Pathological angiogenesis is induced by sustained
Akt signaling and inhibited by rapamycin. Cancer Cell. 10:159–170.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Guba M, von Breitenbuch P, Steinbauer M,
Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S,
Anthuber M, et al: Rapamycin inhibits primary and metastatic tumor
growth by antiangiogenesis: Involvement of vascular endothelial
growth factor. Nat Med. 8:128–135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Milanini J, Viñals F, Pouysségur J and
Pagès G: p42/p44 MAP kinase module plays a key role in the
transcriptional regulation of the vascular endothelial growth
factor gene in fibroblasts. J Biol Chem. 273:18165–18172. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
D’Angelo G, Struman I, Martial J and
Weiner RI: Activation of mitogen-activated protein kinases by
vascular endothelial growth factor and basic fibroblast growth
factor in capillary endothelial cells is inhibited by the
antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc
Natl Acad Sci USA. 92:6374–6378. 1995. View Article : Google Scholar
|
|
60
|
Duesbery NS, Webb CP, Leppla SH, Gordon
VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K,
Paull KD, et al: Proteolytic inactivation of MAP-kinase-kinase by
anthrax lethal factor. Science. 280:734–737. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Vitale G, Bernardi L, Napolitani G, Mock M
and Montecucco C: Susceptibility of mitogen-activated protein
kinase kinase family members to proteolysis by anthrax lethal
factor. Biochem J. 352:739–745. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Duesbery NS, Resau J, Webb CP, Koochekpour
S, Koo HM, Leppla SH and Vande Woude GF: Suppression of
ras-mediated transformation and inhibition of tumor growth and
angiogenesis by anthrax lethal factor, a proteolytic inhibitor of
multiple MEK pathways. Proc Natl Acad Sci USA. 98:4089–4094. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bromberg-White JL, Boguslawski E and
Duesbery NS: Perturbation of mouse retinal vascular morphogenesis
by anthrax lethal toxin. PLoS One. 4:e69562009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bromberg-White JL, Boguslawski E, Hekman
D, Kort E and Duesbery NS: Persistent inhibition of oxygen-induced
retinal neovascularization by anthrax lethal toxin. Invest
Ophthalmol Vis Sci. 52:8979–8992. 2011. View Article : Google Scholar : PubMed/NCBI
|
